Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cell-mediated Immune Responses

Cell-mediated Immune Responses

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Kidney Transplantation Post-Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Multiple Myeloma.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026

Same author

Urolithiasis in patients with cancer.

Nature reviews. Urology·2026

Same author

Framework for the comprehensive screening for endocrine disorders in patients with transfusion-dependent thalassemia in low-resource settings.

Annals of hematology·2025

Same author

Heterogeneity in Methods of Estimating Kidney Function for Cancer Clinical Trial Eligibility.

JAMA network open·2024

Same author

Seronegative celiac disease with transient protein-losing enteropathy and vitamin B12 deficiency in a pediatric patient: Case report.

Clinical case reports·2024

Same author

Chimeric Antigen Receptor (CAR) T-Cell Therapy Use in Patients with Multiple Myeloma and Kidney Failure on Maintenance Hemodialysis: A Report of 2 Cases.

Kidney medicine·2024

Search research articles

Related Experiment Video

Updated: Jun 18, 2025

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

Immunotactoid Glomerulopathy.

Matthew Abramson¹, Aisha Shaikh²

¹Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, NY.

Advances in Kidney Disease and Health

|July 31, 2024

Summary

This summary is machine-generated.

Immunotactoid glomerulopathy (ITG) is a rare kidney disease diagnosed by biopsy, showing unique microtubular deposits. Thorough hematologic workup is crucial for both monoclonal and polyclonal ITG management and prognosis.

Keywords:

Glomerulopathy Hematologic disorder Immunotactoid Microtubule Proteinuria

More Related Videos

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

Related Experiment Videos

Last Updated: Jun 18, 2025

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

Area of Science:

Nephrology
Pathology
Hematology

Background:

Immunotactoid glomerulopathy (ITG) is a rare glomerular disease presenting with proteinuria, hematuria, and kidney dysfunction.
Diagnosis requires kidney biopsy, revealing electron-dense immunoglobulin deposits with hollow-cored microtubules.
ITG is classified as monoclonal or polyclonal based on immunoglobulin deposit immunofluorescence.

Purpose of the Study:

To summarize the key features, diagnostic criteria, and management strategies for Immunotactoid Glomerulopathy.
To highlight the association between ITG subtypes and underlying systemic disorders.
To emphasize the importance of hematologic workup and its impact on ITG prognosis and treatment.

Main Methods:

Review of existing literature and case studies on Immunotactoid Glomerulopathy.
Analysis of diagnostic features, including kidney biopsy findings and immunofluorescence staining.
Evaluation of treatment approaches based on ITG classification and associated hematologic or autoimmune conditions.

Main Results:

Monoclonal ITG is frequently linked to hematologic disorders (lymphoma, plasma cell dyscrasias).
Polyclonal ITG is associated with autoimmune diseases, infections, or hematologic disorders.
Polyclonal ITG carries a higher risk of progression to end-stage kidney disease compared to monoclonal ITG.

Conclusions:

A comprehensive hematologic evaluation is essential for all ITG patients due to strong associations with systemic diseases.
Treatment of monoclonal ITG focuses on achieving hematologic remission, which influences renal response.
Polyclonal ITG management is less defined, and recurrence post-transplant is common, often linked to hematologic relapse.